

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – November 4, 2020 @ 4:00pm

OHCA Webinar

Register for the meeting here:

<https://odot.webex.com/odot/onstage/g.php?MTID=e8f4367350ba553df91e069c0bfba1048>

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

Telephone Conference Participants

DUR Board Members:

Dr. Stephen Anderson –
Dr. Jennifer de los Angeles –
Ms. Jennifer Boyett –
Dr. Markita Broyles –
Dr. Theresa Garton –
Dr. Megan Hanner –
Dr. Lynn Mitchell –
Dr. John Muchmore –
Dr. Lee Muñoz –
Dr. James Osborne –

participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference

Public Access to Meeting via Webex:

Register at:

<https://odot.webex.com/odot/onstage/g.php?MTID=e8f4367350ba553df91e069c0bfba1048>

Or join by phone:

Dial: +1-415-655-0002

Event number: 133 317 0056

Event password: OHCADUR1104

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. October 14, 2020 DUR Minutes – Vote
- B. October 14, 2020 DUR Recommendations Memorandum

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

4. Action Item – 2021 DUR Board Meeting Dates – See Appendix B

- A. 2021 DUR Board Meeting Dates

Items to be presented by Dr. Chandler, Dr. Ha, Dr. Muchmore, Chairman:

5. Update on Medication Coverage Authorization Unit/U.S. Food and Drug Administration (FDA) Safety Alerts – See Appendix C

- A. Pharmacy Helpdesk Activity for October 2020
- B. Medication Coverage Activity for October 2020
- C. U.S. Food and Drug Administration (FDA) Safety Alerts

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Evrysdi™ (Risdiplam) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor) – See Appendix E

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Ford, Chairman:

8. Action Item – Vote to Prior Authorize Epclusa® (Sofosbuvir/Velpatasvir) 200mg/50mg Tablet – See Appendix F

- A. New U.S. Food and Drug Administration (FDA) Approval(s) and Label Update(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Cystadrops® (Cysteamine 0.37% Ophthalmic Solution) and Cystaran™ (Cysteamine 0.44% Ophthalmic Solution) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Daniel, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Mycapssa® (Octreotide) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Zejula® (Niraparib) – See Appendix I

- A. Market News and Updates
- B. Zejula® (Niraparib) Product Summary
- C. Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

12. Annual Review of Multiple Myeloma Medications and 30-Day Notice to Prior Authorize Blenrep (Belantamab Mafodotin-blmf), Darzalex® (Daratumumab), Darzalex Faspro™ (Daratumumab/Hyaluronidase-fihj), Empliciti® (Elotuzumab), Hemady™ (Dexamethasone 20mg Tablet), Ninlaro® (Ixazomib), Sarclisa® (Isatuximab-irfc), and Xpovio® (Selinexor) – See Appendix J

- A. Introduction
- B. Utilization of Multiple Myeloma Medications
- C. Prior Authorization of Multiple Myeloma Medications
- D. Market News and Updates
- E. Product Summaries
- F. Recommendations
- G. Utilization Details of Multiple Myeloma Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Lenvima® (Lenvatinib) – See Appendix K

- A. Introduction
- B. Lenvima® (Lenvatinib) Product Summary
- C. Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. Annual Review of Maintenance Asthma and Chronic Obstructive Pulmonary Disease (COPD) Medications and 30-Day Notice to Prior Authorize AirDuo® Digihaler® (Fluticasone Propionate/Salmeterol), ArmonAir® Digihaler® (Fluticasone Propionate), and Breztri Aerosphere™ (Budesonide/Glycopyrrolate/Formoterol Fumarate) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Maintenance Asthma and COPD Medications
- C. Prior Authorization of Maintenance Asthma and COPD Medications
- D. Market News and Updates
- E. AirDuo® Digihaler® (Fluticasone Propionate/Salmeterol) Product Summary
- F. ArmonAir® Digihaler® (Fluticasone Propionate) Product Summary
- G. Breztri Aerosphere™ (Budesonide/Glycopyrrolate/Formoterol) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of Maintenance Asthma and COPD Medications
- J. Utilization Details of Inhaled Corticosteroids

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

15. Action Item – Annual Review of Atopic Dermatitis (AD) Medications – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of AD Medications
- C. Prior Authorization of AD Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of AD Medications

Items to be presented by Dr. Daniel, Dr. Muchmore, Chairman:

16. Annual Review of Anticoagulants and Platelet Aggregation Inhibitors – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anticoagulants
- G. Utilization Details of Platelet Aggregation Inhibitors

Non-presentation/Questions only:

17. Annual Review of Tepezza® (Teprotumumab-trbw) – See Appendix O

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Tepezza® (Teprotumumab-trbw)
- D. Prior Authorization of Tepezza® (Teprotumumab-trbw)
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Tepezza® (Teprotumumab-trbw)

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Items to be presented by Susan Eads, Dr. Adams, Dr. Muchmore, Chairman:

19. Future Business

A. Nondiscrimination in Health Care Coverage Act

- i. Discussion of the Nondiscrimination in Health Care Coverage Act, which became effective on November 1, 2020 (63 Okla. Stat. §§2560-2565), and the DUR Board's compliance therewith.

B. Upcoming Product and Class Reviews*

- i. Targeted Immunomodulator Agents
- ii. Antidepressants
- iii. Ulcerative Colitis (UC) and Crohn's Disease Medications
- iv. Thrombocytopenia Medications

**Future product and class reviews subject to change.*

20. Adjournment